These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20727234)

  • 1. Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
    Markopoulos C
    Breast Cancer Res; 2010; 12(4):403. PubMed ID: 20727234
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
    Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
    Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
    Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
    Lipton A; Chapman JW; Leitzel K; Garg A; Pritchard KI; Ingle JN; Budd GT; Ellis MJ; Sledge GW; Rabaglio M; Han L; Elliott CR; Shepherd LE; Goss PE; Ali SM
    Cancer; 2017 Jul; 123(13):2444-2451. PubMed ID: 28464211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition.
    Van Poznak C
    Breast Cancer Res; 2010; 12(3):110. PubMed ID: 20584345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
    Coleman R; de Boer R; Eidtmann H; Llombart A; Davidson N; Neven P; von Minckwitz G; Sleeboom HP; Forbes J; Barrios C; Frassoldati A; Campbell I; Paija O; Martin N; Modi A; Bundred N
    Ann Oncol; 2013 Feb; 24(2):398-405. PubMed ID: 23047045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Wenz F
    N Engl J Med; 2009 May; 360(22):2367; author reply 2369-70. PubMed ID: 19474438
    [No Abstract]   [Full Text] [Related]  

  • 9. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Berruti A; Buttigliero C; Dogliotti L
    N Engl J Med; 2009 May; 360(22):2368; author reply 2369-70. PubMed ID: 19484817
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitors and bone health in women with breast cancer.
    Chien AJ; Goss PE
    J Clin Oncol; 2006 Nov; 24(33):5305-12. PubMed ID: 17114665
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
    Markopoulos C; Tzoracoleftherakis E; Polychronis A; Venizelos B; Dafni U; Xepapadakis G; Papadiamantis J; Zobolas V; Misitzis J; Kalogerakos K; Sarantopoulou A; Siasos N; Koukouras D; Antonopoulou Z; Lazarou S; Gogas H
    Breast Cancer Res; 2010; 12(2):R24. PubMed ID: 20398352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
    Kalder M; Ziller V; Kyvernitakis I; Knöll D; Hars O; Hadji P
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):915-23. PubMed ID: 23443254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
    N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
    Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB
    Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
    Tang SC
    Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
    J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of aromatase inhibitors on bone health in breast cancer patients.
    Geisler J; Lønning PE
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):294-9. PubMed ID: 19833206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole.
    Howell A
    Clin Chem; 2012 Apr; 58(4):782-3. PubMed ID: 22334481
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.